Patients with cancer recurrence and progression
| No. | Sex/Age (yr) | Cancer | Stage | DMARDs before cancer diagnosis |
DMARDs right after cancer diagnosis |
Cancer treatment |
DMARDs before recurrence |
Relapse time (yr) |
Cancer treatment after recurrence |
DMARDs after recurrence |
FU (yr) |
Current RA treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/72 | Lung | IV (T4aN0M0) | MTX+LEF+HCQ | Discontinuation | C | HCQ | 1.7 | C | HCQ | 2.6 | Death |
| 2 | F/71 | CBD | III | MTX+SSZ+HCQ | Discontinuation | S+C | No DMARD | 0.9 | C | No DMARD | 1.2 | FU loss |
| 3 | F/39 | Cervix | I | MTX+ADA | Switching→LEF+TC+HCQ | S+C | LEF+TC+HCQ | 1.5 | C | LEF+HCQ | 7.1 | No DMARD |
| 4 | F/57 | Colon | III | MTX+SSZ+HCQ | Switching→ SSZ+HCQ | S+C | MTX+ADA | 2.3 | C | No DMARD | 6.6 | No DMARD |
| 5 | M/50 | CML | Accelerated | MTX+HCQ | Discontinuation | C | No DMARD | 2.4 | C | No DMARD | 8.0 | No DMARD |
| 6 | F/67 | Stomach | I | MTX+LEF | Discontinuation | S | ADA | 2.1 | S | ADA | 7.1 | TCZ |
| 7 | F/66 | Lung | II | MTX+LEF+HCQ | Switching → HCQ | S+C | MTX+HCQ | 1.3 | C | MTX+HCQ | 4.4 | MTX+HCQ |
| 8 | M/80 | Bladder | I | TCZ | Maintenance | S | MTX+LEF | 0.7 | S+C | LEF | 4.6 | MTX |
F: female, M: male, CBD: common bile duct, CML: chronic myelogenous leukemia, DMARDs: disease modifying antirheumatic drugs, MTX: methotrexate, LEF: leflunomide, TCZ: tocilizumab, ADA: adalimumab, HCQ: hydroxychloroquine, SSZ: sulfasalazine, S: surgical therapy, C: chemotherapy, FU: follow-up, RA: rheumatoid arthritis.